Regeneron Pharmaceuticals (NASDAQ:REGN) EVP Marion Mccourt Sells 1,131 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Marion Mccourt sold 1,131 shares of the business’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the sale, the executive vice president directly owned 12,003 shares of the company’s stock, valued at approximately $10,291,252.17. This trade represents a 8.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marion Mccourt also recently made the following trade(s):

• On Wednesday, September 2nd, Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $843.47 on Friday. The firm has a market capitalization of $86.84 billion, a P/E ratio of 20.85, a P/E/G ratio of 1.67 and a beta of 0.20. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The business’s 50-day simple moving average is $734.39 and its 200-day simple moving average is $719.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $12.81 EPS. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently made changes to their positions in REGN. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $26,000. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at $26,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $29,000. Mowery & Schoenfeld Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $29,000. Finally, Trust Co. of Vermont purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth $29,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on REGN. Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Leerink Partners upped their price target on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a research report on Monday, August 17th. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a report on Thursday, July 9th. Finally, Citigroup raised their price objective on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Fourteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $800.36.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported that a Phase 1/2 study combining cemiplimab with SNS-101 has reached completion. The update provides a development milestone, although no efficacy or regulatory data were disclosed, limiting its immediate impact. Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion
• Neutral Sentiment: Industry research projects substantial growth in the global complement-inhibitor market through 2035 and lists Regeneron among the leading companies. The report supports the company’s long-term opportunity but does not provide a new company-specific catalyst. 2026 Complement Inhibitors Market Analysis Report
• Negative Sentiment: Multiple law firms announced or promoted securities class actions involving investors who purchased REGN shares between August 1, 2025, and May 15, 2026. The lawsuits allege that Regeneron and certain executives misrepresented risks surrounding the Phase 3 Fianlimab-Libtayo melanoma trial, including a protocol change and eventual failure to meet its primary endpoint. Investors have until September 14, 2026, to seek lead-plaintiff status. The legal claims may increase reputational, litigation, and potential financial risks, although the allegations have not been proven. Hagens Berman Regeneron Securities Fraud Class Action Alert Robbins Geller Regeneron Investor Alert
• Negative Sentiment: Director Kathryn Guarini and EVP Marion McCourt reported sales totaling roughly $2.34 million. All transactions were executed under pre-arranged Rule 10b5-1 plans, reducing their significance as discretionary bearish signals, but the sales can still weigh on sentiment near the stock’s recent highs. SEC insider transaction filing

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.